Validation of Lithuanian mental health assessment scales

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to validate the Lithuanian versions of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale. Participants aged 18 to 65 with specific schizophrenia diagnoses will be evaluated using these scales alongside established measures like the Positive and Negative Symptoms Scale and the Montreal Cognitive Assessment. The study focuses on assessing the convergent and discriminant validity of these scales to ensure they accurately reflect the symptoms of schizophrenia in the Lithuanian population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age 18 - 65 years old;
* Diagnosis of F20, F25 or F21 according to ICD-10;
* Signed informed consent form.

Exclusion Criteria:

* Age younger than 18 or older than 65 years old;
* Did not sign the informed consent form;
* Legally inactive person
* Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);
* Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)
* Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)

Where it's running

• Lithuanian University of Health Sciences Hospital Kaunas Clinics
  Kaunas, Lithuania Recruiting
• Jonas Montvidas
  Kaunas, Lithuania Recruiting

Study contacts

• Principal investigator: Virginija Adomaitienė, Prof. — Lithuanian University of Health Sciences
• Study coordinator: Jonas Montvidas, MD
• Email: jonas.montvidas@lsmu.lt
• Phone: +37066240919

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using rTMS to treat negative symptoms of schizophrenia

  This study is testing if a new type of brain treatment called rTMS can help reduce negative symptoms in people with schizophrenia.

  Recruiting Centre hospitalier de Ville-Evrard, France · Neuilly-sur-Marne · NCT06595654

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.